Our product, lasofoxifene, is a once a week, local, low dose, non-estrogen soft gel vaginal treatment for VVA that achieves both patients' and physicians' ideal profile, especially in breast cancer survivors.
Vaginal Formulation Improves Upon Pfizer's Well Studied But Unlaunched Oral Product
Azure owns the exclusive license to all topical uses of the well studied, heavily invested but unlaunched SERM, lasofoxifene. Our vaginal formulation utilizes the proven efficacy of Pfizer's oral lasofoxifene in the treatment of vaginal atrophy in postmenopausal women.
Pfizer's Oral Lasofoxifene Clinical Studies
Over 15,000 Postmenopausal Women
Over 27,000 Years Patient Exposure
40 Independent Trials
Efficacy & Safety Demonstrated for Treatment of VVA
We Designed Our Product to Meet Patient and Physician Preferences
We conducted primary market research of both physicians and postmenopausal women to identify the desired product features for treatment of VVA.
Patient Preferences
Once Per Week
Easy Administration
No Leakage
Eco-Friendly Material
Physician Preferences
Non Estrogenic on Uterus
No Systemic Side Effects
Suitable for Breast Cancer Survivors
Adequate Distribution to Vaginal Tissue
This valuable market research was used in developing our formulations which were tested in vivo. These animal studies confirmed efficacy.
Our Game Changer: A Locally Delivered Product for a Local Condition
Azure's local low-dose lasofoxifene offers many advantages over the currently available prescription treatments.
Accelerating Delivery Of Our Product
At Azure, we are committed to addressing the unmet needs of women suffering from VVA, especially the 3.5 million breast cancer survivors who have limited treatment options. We are poised and well positioned to bring our product to market quickly with minimal investment for its clinical development:
Completed vaginal formulation - weekly soft gel capsule. Meets all patient and physician needs, especially for breast cancer survivors.
Minimized risk by capitalizing on Pfizer's oral form of lasofoxifene (manufacturing processes, VVA efficacy and safety).
Manufactured technical batches - materials sourced and production ready for clinical program.
Secured new IP that extends proprietary protection.
Limited generic entry with a local product that is non detectable in the blood.
May 2026: Now Enrolling for Phase 2 Clinical Study of Lasofoxifene
We are conducting a Phase 2 clinical study of lasofoxifene. The study will be evaluating this potential new treatment in healthy adult women who are postmenopausal or who have had a bilateral oophorectomy (both ovaries removed) and are experiencing vaginal dryness, discomfort and painful intercourse associated with VVA.
This study aims to further understand the safety and effectiveness of lasofoxifene in women experiencing these common menopausal symptoms.
Azure's Lasofoxifene will be a game changer offering advantages over all competition. We will be introducing a truly differentiated product that has been long needed, especially for women with breast concerns. This is a clinic ready program starting with volumes of efficacy and safety data with an expedited development timeline.